| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
9,411,000 |
| Market
Cap: |
2.03(M) |
| Last
Volume: |
2,864,142 |
Avg
Vol: |
937,479 |
| 52
Week Range: |
$0.2158 - $0.2158 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Appliances & Equipment |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Rockwell Medical is a commercial-stage, biopharmaceutical company developing and commercializing its parenteral iron technology platform, Ferric Pyrophosphate Citrate (FPC). Co. is also a supplier of hemodialysis concentrate products to kidney dialysis clinics in the U.S. Co. has two therapies, Triferic and Triferic AVNU, which are developed from its FPC platform. Co. markets both products to kidney dialysis centers for their patients receiving dialysis. Co. has filed an Investigational New Drug Application to conduct a Phase II trial for the treatment of iron deficiency anemia in patients outside of dialysis, who are receiving intravenous medications in the home infusion setting.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rbi Opportunities Fund Ii, Llc |
|
– – – |
2019-03-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,655,759 |
|
- |
|
| Paul Stuart M |
Chief Executive Officer |
• • – |
2019-03-15 |
4 |
D |
$5.21 |
$178,844 |
D/D |
(34,327) |
353,798 |
|
- |
|
| Ravich Mark H |
Director |
– • – |
2018-12-21 |
4 |
A |
$0.00 |
$0 |
D/D |
22,200 |
336,950 |
|
- |
|
| Ravich Mark H |
Director |
– • – |
2018-12-21 |
4 |
D |
$0.00 |
$0 |
I/I |
(44,400) |
0 |
|
- |
|
| Smith Angus W. |
Chief Financial Officer |
• – – |
2018-11-28 |
4 |
A |
$0.00 |
$0 |
D/D |
166,667 |
166,667 |
|
- |
|
| Curfman Matthew J. |
See Footnotes 1 and 2 |
– – – |
2018-10-15 |
4 |
B |
$0.00 |
$0 |
I/I |
5,541,562 |
5,541,562 |
0.01 |
- |
|
| Gupta Ajay |
Sr. VP & Chief Scientific Off. |
• – – |
2018-10-07 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
590,949 |
|
- |
|
| Kull David |
Principal Accounting Officer |
• – – |
2018-09-20 |
4 |
D |
$4.22 |
$17,429 |
D/D |
(4,130) |
3,270 |
|
- |
|
| Kull David |
Principal Accounting Officer |
• – – |
2018-09-20 |
4 |
OE |
$3.09 |
$15,450 |
D/D |
5,000 |
7,400 |
|
- |
|
| Paul Stuart M |
Chief Executive Officer |
• • – |
2018-09-04 |
4 |
A |
$0.00 |
$0 |
D/D |
388,125 |
388,125 |
|
- |
|
| Curfman Matthew J. |
See Footnote 1 |
– – • |
2018-06-28 |
4 |
B |
$4.37 |
$34,726 |
I/I |
7,940 |
36,249 |
1.5 |
- |
|
| Curfman Matthew J. |
See Footnote 1 |
– – • |
2018-06-27 |
4 |
B |
$4.73 |
$21,857 |
I/I |
4,621 |
34,423 |
1.5 |
- |
|
| Klema Thomas E |
Vice President, CFO |
• – – |
2017-12-15 |
4 |
D |
$6.60 |
$568,755 |
D/D |
(86,175) |
671,492 |
|
- |
|
| Klema Thomas E |
Vice President, CFO |
• – – |
2017-12-15 |
4 |
OE |
$6.50 |
$568,750 |
D/D |
87,500 |
757,667 |
|
- |
|
| Boyd Ronald D |
Director |
– • – |
2017-12-15 |
4 |
D |
$6.60 |
$162,505 |
D/D |
(24,622) |
42,678 |
|
- |
|
| Boyd Ronald D |
Director |
– • – |
2017-12-15 |
4 |
OE |
$6.50 |
$162,500 |
D/D |
25,000 |
67,300 |
|
- |
|
| Chioini Robert L |
Chairman, President and CEO |
• • – |
2017-12-15 |
4 |
D |
$6.60 |
$2,112,502 |
D/D |
(320,076) |
2,549,907 |
|
- |
|
| Chioini Robert L |
Chairman, President and CEO |
• • – |
2017-12-15 |
4 |
OE |
$6.50 |
$2,112,500 |
D/D |
325,000 |
2,869,983 |
|
- |
|
| Curfman Matthew J. |
See Footnote 1 |
– – • |
2017-12-15 |
4 |
S |
$6.53 |
$235 |
D/D |
(36) |
176,376 |
|
- |
|
| Bagley Patrick J |
Director |
– • – |
2017-12-15 |
4 |
D |
$6.60 |
$325,004 |
D/D |
(49,243) |
116,307 |
|
- |
|
| Bagley Patrick J |
Director |
– • – |
2017-12-15 |
4 |
OE |
$6.50 |
$325,000 |
D/D |
50,000 |
165,550 |
|
- |
|
| Curfman Matthew J. |
See Footnote 1 |
– – • |
2017-08-10 |
4 |
B |
$6.34 |
$3,836 |
I/I |
605 |
42,100 |
1.42 |
- |
|
| Klema Thomas E |
Vice President, CFO |
• – – |
2017-06-21 |
4 |
D |
$7.20 |
$383,566 |
D/D |
(53,273) |
670,167 |
|
- |
|
| Gupta Ajay |
Chief Scientific Officer |
• – – |
2017-06-21 |
4 |
D |
$7.20 |
$498,370 |
D/D |
(69,218) |
490,949 |
|
- |
|
| Pratt Raymond Dennis |
VP of Drug Development |
• – – |
2017-06-21 |
4 |
D |
$7.20 |
$548,856 |
D/D |
(76,230) |
317,970 |
|
- |
|
171 Records found
|
|
Page 4 of 7 |
|
|
